Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain
Katrina Weston‐Green, Xu‐Feng Huang, Chao Deng
PLoS ONE (2012) Vol. 7, Iss. 3, pp. e33548-e33548
Open Access | Times Cited: 90

Showing 26-50 of 90 citing articles:

Cross talk about the role of Neuropeptide Y in CNS disorders and diseases
Rajeshwari Bale, Gaurav Doshi
Neuropeptides (2023) Vol. 102, pp. 102388-102388
Closed Access | Times Cited: 12
Exploring the therapeutic potential of chlorogenic acid in alleviating olanzapine-induced metabolic syndrome in rats: a key role of hypothalamic satiety proteins
Zeinab Ebrahimian, Bibi Marjan Razavi, Seyed Ali Mousavi Shaegh, et al.
Nutritional Neuroscience (2025), pp. 1-20
Closed Access
Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
Heidi N. Boyda, Ric M. Procyshyn, Catherine C.Y. Pang, et al.
PLoS ONE (2013) Vol. 8, Iss. 1, pp. e53459-e53459
Open Access | Times Cited: 39
Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways
Jiamei Lian, Michael De Santis, Meng Xiao He, et al.
Pharmacological Research (2015) Vol. 95-96, pp. 20-26
Closed Access | Times Cited: 36
Gut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia
Cuirong Zeng, Ping Yang, Ting Cao, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 106, pp. 110097-110097
Closed Access | Times Cited: 32
Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics
Michał Lis, Bartłomiej Stańczykiewicz, Paweł Liśkiewicz, et al.
Psychoneuroendocrinology (2020) Vol. 119, pp. 104744-104744
Open Access | Times Cited: 28
Reductions in midbrain GABAergic and dopamine neuron markers are linked in schizophrenia
Tertia D. Purves-Tyson, Amelia M. Brown, Christin Weissleder, et al.
Molecular Brain (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 26
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
Georgios Schoretsanitis, Céline Dubath, Claire Grosu, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 130, Iss. 4, pp. 531-541
Open Access | Times Cited: 16
Olanzapine attenuates 5-HT2cR and GHSR1a interaction to increase orexigenic hypothalamic NPY: Implications for neuronal molecular mechanism of metabolic side effects of antipsychotics
Xiaoli Liu, Lan Xia, Xinyou Zhang, et al.
Behavioural Brain Research (2024) Vol. 463, pp. 114885-114885
Closed Access | Times Cited: 3
Effect of short and long-term treatment with antipsychotics on orexigenic/anorexigenic neuropeptides expression in the rat hypothalamus
Ewa Rojczyk, Artur Pałasz, Ryszard Wiaderkiewicz
Neuropeptides (2015) Vol. 51, pp. 31-42
Closed Access | Times Cited: 31
Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance
Andrea del Campo, Catalina Bustos, Carolina Mascayano, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 29
Disrupted sphingolipid metabolism following acute clozapine and olanzapine administration
Katrina Weston‐Green, Ilijana Babic, Michael De Santis, et al.
Journal of Biomedical Science (2018) Vol. 25, Iss. 1
Open Access | Times Cited: 28
Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate
Meng Xiao He, Xu‐Feng Huang, Guanbin Gao, et al.
Psychoneuroendocrinology (2019) Vol. 104, pp. 286-299
Closed Access | Times Cited: 26
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: Temporally based hypothesis
Nagesh Pai, Chao Deng, Shae‐Leigh Vella, et al.
Asian Journal of Psychiatry (2012) Vol. 5, Iss. 4, pp. 315-318
Closed Access | Times Cited: 29
Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?
Maria-Cristina Porfirio, Juliana-Paula Gomes de Almeida, Maddalena Stornelli, et al.
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 2167-2174
Open Access | Times Cited: 27
Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway
Xuemei Liu, Xiaomin Zhao, Chao Deng, et al.
Acta Pharmacologica Sinica (2019) Vol. 40, Iss. 8, pp. 1049-1057
Open Access | Times Cited: 25
The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor
Keita Tagami, Yohei Kashiwase, Akinobu Yokoyama, et al.
Neuropeptides (2015) Vol. 58, pp. 93-101
Open Access | Times Cited: 23
Association Study of GABAA α2 Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain
Clement C. Zai, Arun K. Tiwari, Nabilah I. Chowdhury, et al.
Journal of Clinical Psychopharmacology (2014) Vol. 35, Iss. 1, pp. 7-12
Closed Access | Times Cited: 22
Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs
Nana Li, Ting Cao, Xiangxin Wu, et al.
Frontiers in Pharmacology (2020) Vol. 10
Open Access | Times Cited: 19
Mechanistic/mammalian target of rapamycin and side effects of antipsychotics: insights into mechanisms and implications for therapy
Chuanjun Zhuo, Yong Xu, Weihong Hou, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 12
The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review
Ruqin Zhou, Meng Xiao He, Jun Fan, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 12
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance
Jaedeok Kim, Nayoung Lee, Sang Bum Suh, et al.
BMB Reports (2022) Vol. 55, Iss. 6, pp. 293-298
Open Access | Times Cited: 11
An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine
Claire Wu, Jessica W. Y. Yuen, Heidi N. Boyda, et al.
PLoS ONE (2014) Vol. 9, Iss. 9, pp. e107116-e107116
Open Access | Times Cited: 20
Olanzapine-Activated AMPK Signaling in the Dorsal Vagal Complex Is Attenuated by Histamine H1 Receptor Agonist in Female Rats
Meng Xiao He, Qingsheng Zhang, Chao Deng, et al.
Endocrinology (2014) Vol. 155, Iss. 12, pp. 4895-4904
Open Access | Times Cited: 20
Endocannabinoid Signaling at Hypothalamic Steroidogenic Factor-1/Proopiomelanocortin Synapses Is Sex- and Diet-Sensitive
Carolina Fabelo, Jennifer Hernandez, R Chang, et al.
Frontiers in Molecular Neuroscience (2018) Vol. 11
Open Access | Times Cited: 20

Scroll to top